Themis Medicare Intrinsic Value
THEMISMED • Healthcare
Current Stock Price
₹78.50
Primary Intrinsic Value
₹196.25
Market Cap
₹70.7 Cr
+150.0%
Upside
Median Value
₹196.25
Value Range
₹89 - ₹196
Assessment
Trading Below Calculated Value
Safety Margin
60.0%
THEMISMED Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹196.25 | ₹176.62 - ₹215.88 | +150.0% | Book Value/Share: ₹447.78, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹157.00 | ₹141.30 - ₹172.70 | +100.0% | Revenue/Share: ₹368.89, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹88.89 | ₹80.00 - ₹97.78 | +13.2% | EBITDA: ₹8.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹196.25 | ₹157.00 - ₹235.50 | +150.0% | CF Growth: 5.0%, Discount: 15% |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
THEMISMED Intrinsic Value Analysis
What is the intrinsic value of THEMISMED?
Based on our comprehensive analysis using 4 different valuation methods, the estimated intrinsic value of Themis Medicare (THEMISMED) is ₹196.25 (median value). With the current market price of ₹78.50, this represents a +150.0% variance from our estimated fair value.
The valuation range spans from ₹88.89 to ₹196.25, indicating ₹88.89 - ₹196.25.
Is THEMISMED undervalued or overvalued?
Based on our multi-method analysis, Themis Medicare (THEMISMED) appears to be trading below calculated value by approximately 150.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 10.48 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -4.0% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -4.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.56x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Themis Medicare
Additional stock information and data for THEMISMED
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹35 Cr | ₹29 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹22 Cr | ₹14 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹16 Cr | ₹4 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹34 Cr | ₹26 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹57 Cr | ₹49 Cr | Positive Free Cash Flow | 8/10 |